tiprankstipranks
Advertisement
Advertisement

MBRX Stock Latest News

Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
The FlyMoleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
2d ago
MBRX
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
PremiumCompany Announcements
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
2d ago
8K
MBRX
Moleculin Biotech files to sell 4.57M shares of common stock, warrants
PremiumThe Fly
Moleculin Biotech files to sell 4.57M shares of common stock, warrants
4d ago
MBRX
Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A
PremiumThe Fly
Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A
1M ago
MBRX
Moleculin Biotech Updates Investors With New Presentation
PremiumCompany Announcements
Moleculin Biotech Updates Investors With New Presentation
1M ago
8K
MBRX
Moleculin Biotech Reports Promising Annamycin AML Trial Data
PremiumCompany AnnouncementsMoleculin Biotech Reports Promising Annamycin AML Trial Data
1M ago
8K
MBRX
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
Premium
Company Announcements
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
2M ago
8K
MBRX
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
Premium
Company Announcements
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
2M ago
8K
MBRX
Moleculin Biotech Releases Updated Investor Information Presentation
PremiumCompany Announcements
Moleculin Biotech Releases Updated Investor Information Presentation
2M ago
8K
MBRX
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
PremiumCompany Announcements
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
2M ago
8K
MBRX
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target
PremiumRatings
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target
3M ago
MBRX
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target
PremiumRatings
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target
3M ago
MBRX
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
PremiumThe FlyMoleculin Biotech expects first unblinding of MIRACLE trial data by June 30
3M ago
MBRX
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
Premium
Company Announcements
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
3M ago
8K
MBRX
Moleculin announces publication on cardiac safety profiloe of annamycin
Premium
The Fly
Moleculin announces publication on cardiac safety profiloe of annamycin
3M ago
MBRX
Moleculin highlights favorable cardiac safety data for Annamycin
PremiumCompany Announcements
Moleculin highlights favorable cardiac safety data for Annamycin
3M ago
8K
MBRX
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
PremiumThe Fly
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
3M ago
MBRX
Moleculin Secures New Hong Kong Patent for Annamycin
PremiumCompany Announcements
Moleculin Secures New Hong Kong Patent for Annamycin
3M ago
8K
MBRX
Moleculin Highlights Promising Preclinical Data for L-ANN
PremiumCompany Announcements
Moleculin Highlights Promising Preclinical Data for L-ANN
3M ago
8K
MBRX
Moleculin Biotech Stockholders Approve Warrant Share Issuance
PremiumCompany AnnouncementsMoleculin Biotech Stockholders Approve Warrant Share Issuance
4M ago
8K
MBRX
Moleculin Biotech management to meet with Maxim
Premium
The Fly
Moleculin Biotech management to meet with Maxim
4M ago
MBRX
Moleculin Biotech files to sell 6.37M shares of common stock for holders
Premium
The Fly
Moleculin Biotech files to sell 6.37M shares of common stock for holders
4M ago
MBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >